Literature DB >> 17418070

Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size.

Laura Rosiñol1, M Teresa Cibeira, Silvia Montoto, María Rozman, Jordi Esteve, Xavier Filella, Joan Bladé.   

Abstract

OBJECTIVE: To investigate the predictors of monoclonal gammopathy of undetermined significance (MGUS) by considering not only the initial features but also the pattern of evolution of the M protein during the first years after diagnosis. PATIENTS AND METHODS: This study consisted of 359 patients diagnosed as having MGUS at a single institution. Patients who showed a definite and progressive increase in their M protein size according to serum electrophoresis during the first 3 years of follow-up were considered to have evolving MGUS, whereas all others were considered to have nonevolving MGUS.
RESULTS: Of the 359 patients, 330 had nonevolving MGUS, whereas 29 fulfilled the criteria for evolving MGUS. Overall, 32 patients developed malignant transformation. The progression rates at 10 and 20 years of follow-up for the evolving and the nonevolving types were 55% vs 10% and 80% vs 13%, respectively. Multivariate analysis revealed that the features significantly associated with a higher risk of progression were evolving MGUS (relative risk [RR], 12.14; P<.001), IgA MGUS (RR, 2.93; P=.006), and M protein concentration (RR, 2.18; P=.04).
CONCLUSION: The evolutionary pattern of serum M protein (progressive increasing vs stable) during the first years of follow-up is the most important risk factor for disease progression in patients with MGUS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17418070     DOI: 10.4065/82.4.428

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  19 in total

1.  Incidental finding of monoclonal gammopathy in blood donors: a follow-up study.

Authors:  Massimo La Raja; Monica Barcobello; Nicola Bet; Paolo Dolfini; Marina Florean; Federica Tomasella; Vincenzo De Angelis; Luca Mascaretti
Journal:  Blood Transfus       Date:  2012-03-28       Impact factor: 3.443

Review 2.  Pathogenesis beyond the cancer clone(s) in multiple myeloma.

Authors:  Giada Bianchi; Nikhil C Munshi
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

Review 3.  Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma.

Authors:  Brendan M Weiss; W Michael Kuehl
Journal:  Expert Rev Hematol       Date:  2010-04       Impact factor: 2.929

Review 4.  The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.

Authors:  Niels W C J van de Donk; Antonio Palumbo; Hans Erik Johnsen; Monika Engelhardt; Francesca Gay; Henrik Gregersen; Roman Hajek; Martina Kleber; Heinz Ludwig; Gareth Morgan; Pellegrino Musto; Torben Plesner; Orhan Sezer; Evangelos Terpos; Anders Waage; Sonja Zweegman; Hermann Einsele; Pieter Sonneveld; Henk M Lokhorst
Journal:  Haematologica       Date:  2014-03-21       Impact factor: 9.941

Review 5.  Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Oncology (Williston Park)       Date:  2011-06       Impact factor: 2.990

Review 6.  From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention.

Authors:  Ola Landgren; Robert A Kyle; S Vincent Rajkumar
Journal:  Clin Cancer Res       Date:  2011-03-15       Impact factor: 12.531

7.  85-year-old man with epistaxis.

Authors:  Matthew J Butts; Joseph H Skalski; Christopher M Wittich
Journal:  Mayo Clin Proc       Date:  2011-04       Impact factor: 7.616

Review 8.  How I manage monoclonal gammopathy of undetermined significance.

Authors:  Ronald S Go; S Vincent Rajkumar
Journal:  Blood       Date:  2017-11-28       Impact factor: 22.113

9.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

Review 10.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.

Authors:  Amit Agarwal; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2012-12-05       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.